Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018037581) RETINOPATHY THERAPEUTIC AGENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/037581 International Application No.: PCT/JP2016/086658
Publication Date: 01.03.2018 International Filing Date: 09.12.2016
IPC:
A61K 45/00 (2006.01) ,A61K 31/382 (2006.01) ,A61K 31/70 (2006.01) ,A61K 31/7042 (2006.01) ,A61K 31/7048 (2006.01) ,A61P 3/10 (2006.01) ,A61P 27/02 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
38
having sulfur as a ring hetero atom
382
having six-membered rings, e.g. thioxanthenes
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7042
Compounds having saccharide radicals and heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7042
Compounds having saccharide radicals and heterocyclic rings
7048
having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
Applicants:
合同会社カルナヘルスサポート CARNA HEALTH SUPPORT LLC. [JP/JP]; 福岡県福岡市博多区綱場町1-16多田ビル5階 Tada Bldg. 5F, 1-16, Tsunaba-machi, Hakata-ku, Fukuoka-shi, Fukuoka 8120024, JP
Inventors:
井口 登與志 INOGUCHI Toyoshi; JP
前田 泰孝 MAEDA Yasutaka; JP
牧 俊允 MAKI Toshinobu; JP
園田 紀之 SONODA Noriyuki; JP
Agent:
▲高▼津 一也 TAKATSU Kazuya; JP
Priority Data:
2016-16565626.08.2016JP
Title (EN) RETINOPATHY THERAPEUTIC AGENT
(FR) AGENT THÉRAPEUTIQUE POUR LE TRAITEMENT DE LA RÉTINOPATHIE
(JA) 網膜症治療剤
Abstract:
(EN) [Problem] To provide a therapeutic agent for treating and/or improving retinopathy caused by glucose. [Solution] This therapeutic agent for retinopathy caused by glucose is characterized by having a sodium / glucose cotransporter 2 inhibitor (SGLT2 inhibitor) as the active component. This therapeutic agent is used at a normal dosage, or at a low dosage, less than or equal to the normal dose, at which no fall in blood sugar is observed.
(FR) Le problème abordé par la présente invention est de pourvoir à un agent thérapeutique pour le traitement et/ou l'amélioration d'une rétinopathie provoquée par le glucose. La solution selon l'invention porte sur un agent thérapeutique pour le traitement d'une rétinopathie provoquée par le glucose caractérisé en ce qu'il contient un inhibiteur du cotransporteur de sodium/glucose 2 (inhibiteur de SGLT2) à titre de principe actif. L'agent thérapeutique selon l'invention est utilisé à une dose normale, ou à une faible dose, inférieure ou égale à la dose normale, à laquelle aucune chute de glycémie n'est observée.
(JA) 【課題】グルコースに起因する網膜症を治療及び/又は改善する治療剤を提供すること。 【解決手段】ナトリウム/グルコース共輸送体2阻害物質(SGLT2阻害物質)を有効成分とすることを特徴とするグルコースに起因する網膜症の治療剤であり、通常投与量や、それ以下の血糖降下が認められない低用量で用いられる。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)